Europe Pharma Intelligence Center

The CHMP has issued a positive opinion recommending marketing authorization for Jascayd (nerandomilast) for adults with IPF and PPF in the EU.

The EMA Management Board welcomed the Agency's support to African regulators during the Ebola outbreak in the Democratic Republic of Congo and Uganda caused by the Bundibugyo virus.

EMA will participate in the Amsterdam Canal Parade on August 1, 2026, under the banner "United for Health," marking the agency's most visible public commitment to diversity and inclusion. EMA announcement

The European Union has secured emergency deliveries of the experimental antiviral treatment Favipiravir for hantavirus .

In 2022, U.S. prices across all drugs were 278 percent of prices in the 33 OECD comparison countries , making the U.S. the highest-priced market in that peer set.

Nadia Harbeck's ESMO Asia keynote reinforces the centrality of precision medicine in oncology, with biomarker-driven therapies and early detection as key R&D priorities.

MFN pricing ties U.S. drug prices to those in select high-income countries, creating immediate downward pressure on list prices and forcing launch-price decisions in ex-U.S. markets to carry direct U.S. consequences.

BioCryst added Navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development for hereditary angioedema (HAE), to its rare disease pipeline, as disclosed in a SEC filing .

The EU pharmaceutical package revision aims to ensure timely and equitable access to safe, effective, and affordable medicines for all patients across the EU , while enhancing supply security.